Skip to content
Back to CLOV

Clover Health Investments, Corp.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
42
Purchases
0
Sales
42
Purchase value
$0.00
Sale value
$8.82M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Joseph Clay ThorntonChief Financial Officer
4
Filed Nov 17, 2026Period of report Nov 16, 20260001801170-26-000311
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 16, 2026
Class A Common Stock22,099$4.97$109.83K1,551,783Direct
Open on SEC EDGAR
Karen SoaresChief Legal Officer
4Rule 10b5-1 plan disclosed
Filed Oct 20, 2026Period of report Oct 20, 20260001999086-26-000034
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 20, 2026
Class A Common StockF1F219,275$4.66$89.82K1,573,423Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.45 to $4.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Oct 20, 2026Period of report Oct 19, 20260001839066-26-000057
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 19, 2026
Class A Common StockF1F24,066$4.41$17.93K2,770,351Direct
Filing footnotes · 2
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.32 to $4.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Andrew ToyDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Oct 19, 2026Period of report Oct 15, 20260001801170-26-000284
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 15, 2026
Class A Common StockF1F262,176$4.68$290.98K9,078,334Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 15, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on October 15, 2024. The restricted stock units vest quarterly, with a final vesting on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Karen SoaresChief Legal Officer
4Rule 10b5-1 plan disclosed
Filed Oct 19, 2026Period of report Oct 15, 20260001801170-26-000282
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 15, 2026
Class A Common StockF1F214,673$4.68$68.67K1,592,698Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 15, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on October 15, 2024. The restricted stock units vest quarterly, with a final vesting on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Joseph Clay ThorntonInterim CFO
4Rule 10b5-1 plan disclosed
Filed Oct 19, 2026Period of report Oct 15, 20260001801170-26-000280
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 15, 2026
Class A Common StockF1F24,591$4.68$21.49K1,244,935Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on October 15, 2026. The RSUs were originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Conrad WaiCEO, Counterpart Health
4Rule 10b5-1 plan disclosed
Filed Oct 19, 2026Period of report Oct 15, 20260001801170-26-000278
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 15, 2026
Class A Common StockF1F223,627$4.68$110.57K1,042,072Direct
Filing footnotes · 3
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. F3Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Oct 19, 2026Period of report Oct 15, 20260001801170-26-000276
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 15, 2026
Class A Common StockF1F218,273$4.68$85.52K2,774,417Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 15, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on October 15, 2024. The restricted stock units vest quarterly, with a final vesting on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Oct 7, 2026Period of report Oct 7, 20260001839066-26-000054
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 7, 2026
Class A Common StockF1F22,006$4.63$9.29K2,792,690Direct
Filing footnotes · 2
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.54 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Oct 5, 2026Period of report Oct 5, 20260001839066-26-000052
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 5, 2026
Class A Common StockF18,750$4.42$38.68K2,794,696Direct
Filing footnotes · 1
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting of 6.25% of restricted stock units (the "RSUs") on October 3, 2026. The RSUs were originally granted to the Reporting Person on January 3, 2023, with a final vesting on January 3, 2027, subject to the continued service of the Reporting Person on such final vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Open on SEC EDGAR
Andrew ToyDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Oct 1, 20260001801170-26-000242
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 1, 2026
Class A Common StockF1F2318,806$4.19$1.34M9,140,510Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the quarterly vesting on October 1, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on January 1, 2023. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Sep 18, 2026Period of report Sep 17, 20260001839066-26-000047
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 17, 2026
Class A Common StockF11,921$4.56$8.76K2,803,446Direct
Filing footnotes · 1
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
Open on SEC EDGAR
Joseph Frank OldakowskiVP OF FINANCE AND CONTROLLER
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 16, 20260001801170-26-000223
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 16, 2026
Class A Common StockF13,170$4.64$14.71K275,897Direct
Filing footnotes · 1
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Open on SEC EDGAR
Conrad WaiCEO, Counterpart Health
4Rule 10b5-1 plan disclosed
Filed Sep 16, 2026Period of report Sep 15, 20260001971702-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Class A Common StockF1F2300,000$4.72$1.42M1,170,056IndirectBy Trust.
Filing footnotes · 2
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.60 to $5.06, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. F2Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.
Open on SEC EDGAR
Karen SoaresChief Legal Officer
4Rule 10b5-1 plan disclosed
Filed Sep 15, 2026Period of report Sep 15, 20260001999086-26-000031
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Class A Common StockF1F26,846$4.78$32.72K1,607,371Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the final vesting of 6.25% of restricted stock units originally granted to the Reporting Person on September 15, 2022. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Sep 15, 2026Period of report Sep 15, 20260001839066-26-000045
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Class A Common StockF1F29,273$4.78$44.32K2,805,367Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the final 6.25% of restricted stock units (the "RSUs") on September 15, 2026. The RSUs were originally granted to the Reporting Person on September 16, 2022. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Joseph Frank OldakowskiVP OF FINANCE AND CONTROLLER
4
Filed Sep 14, 2026Period of report Sep 14, 20260001801170-26-000218
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 14, 2026
Class A Common Stock20,000$5.16$103.20K279,067Direct
Open on SEC EDGAR
Joseph Clay ThorntonInterim CFO
4Rule 10b5-1 plan disclosed
Filed Aug 17, 2026Period of report Aug 17, 20260001801170-26-000207
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 17, 2026
Class A Common StockF1F217,775$4.39$78.03K1,249,526Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on August 16, 2026. The RSUs were originally granted to the Reporting Person on February 16, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on February 16, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.29 to $4.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Andrew ToyDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Aug 10, 2026Period of report Aug 10, 20260001838733-26-000028
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 10, 2026
Class A Common StockF1F287,798$4.65$408.26K9,459,316Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the final vesting on August 8, 2026 of 6.25% of restricted stock units originally granted to the Reporting Person on August 8, 2022. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.61 to $4.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Karen SoaresChief Legal Officer
4Rule 10b5-1 plan disclosed
Filed Jul 20, 2026Period of report Jul 20, 20260001999086-26-000021
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 20, 2026
Class A Common StockF1F251,700$4.51$233.17K1,505,522Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jul 17, 2026Period of report Jul 17, 20260001839066-26-000039
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 17, 2026
Class A Common StockF1F24,839$4.53$21.92K2,814,640Direct
Filing footnotes · 2
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.35 to $4.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Andrew ToyDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Jul 16, 2026Period of report Jul 15, 20260001801170-26-000179
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Class A Common StockF1F262,711$4.67$292.86K9,547,114Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Conrad WaiCEO, Counterpart Health
4Rule 10b5-1 plan disclosed
Filed Jul 16, 2026Period of report Jul 15, 20260001801170-26-000178
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Class A Common StockF1F224,215$4.67$113.08K1,145,699Direct
Filing footnotes · 3
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. F3Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jul 16, 2026Period of report Jul 15, 20260001801170-26-000176
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Class A Common StockF1F213,119$4.67$61.27K2,819,479Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on July 15, 2026. The RSUs were originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Karen SoaresChief Legal Officer
4Rule 10b5-1 plan disclosed
Filed Jul 16, 2026Period of report Jul 15, 20260001801170-26-000175
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Class A Common StockF1F210,519$4.67$49.12K1,557,222Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Joseph Clay ThorntonInterim CFO
4Rule 10b5-1 plan disclosed
Filed Jul 16, 2026Period of report Jul 15, 20260001801170-26-000174
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Class A Common StockF1F24,630$4.67$21.62K1,212,954Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on July 15, 2026. The RSUs were originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jul 9, 2026Period of report Jul 8, 20260001839066-26-000033
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 8, 2026
Class A Common StockF12,384$4.68$11.16K2,832,598Direct
Filing footnotes · 1
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jul 6, 2026Period of report Jul 3, 20260001839066-26-000031
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 6, 2026
Class A Common StockF16,229$5.26$32.76K2,834,982Direct
Filing footnotes · 1
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units (the "RSUs") on July 3, 2026. The RSUs were originally granted to the Reporting Person on January 3, 2023. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on January 1, 2027, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Open on SEC EDGAR
Andrew ToyDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Jul 1, 2026Period of report Jul 1, 20260001838733-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Class A Common StockF1313,476$5.32$1.67M9,609,825Direct
Filing footnotes · 1
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on January 1, 2023. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on January 1, 2027, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jun 18, 2026Period of report Jun 17, 20260001839066-26-000024
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 17, 2026
Class A Common StockF12,360$4.78$11.28K2,841,211Direct
Filing footnotes · 1
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.87, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:
Open on SEC EDGAR
Joseph Frank OldakowskiVP OF FINANCE AND CONTROLLER
4Rule 10b5-1 plan disclosed
Filed Jun 17, 2026Period of report Jun 16, 20260001801170-26-000161
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 16, 2026
Class A Common StockF112,102$4.86$58.82K299,067Direct
Filing footnotes · 1
  1. F1The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jun 16, 2026Period of report Jun 15, 20260001839066-26-000022
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 15, 2026
Class A Common StockF1F26,350$4.61$29.27K2,843,571Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.61 to $4.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Karen SoaresChief Legal Officer
4Rule 10b5-1 plan disclosed
Filed Jun 16, 2026Period of report Jun 15, 20260001801170-26-000151
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 15, 2026
Class A Common StockF1F24,681$4.61$21.58K1,567,741Direct
Filing footnotes · 2
  1. F1The sales reported on this Form 4 represent shares of Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.61 to $4.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jun 11, 2026Period of report Jun 11, 20260001839066-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 11, 2026
Class A Common StockF17,289$4.91$35.79K2,849,921Direct
Filing footnotes · 1
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.15, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:
Open on SEC EDGAR
Conrad WaiCEO, Counterpart Health
4Rule 10b5-1 plan disclosed
Filed May 28, 2026Period of report May 28, 20260001971702-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 28, 2026
Class A Common StockF1F2220,426$3.99$879.50K1,390,056IndirectBy Trust.
Filing footnotes · 2
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $3.92 to $4.04, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. F2Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.
Open on SEC EDGAR
Carladenise Armbrister EdwardsDirector
4
Filed May 19, 2026Period of report May 18, 20260001801170-26-000131
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 18, 2026
Class A Common StockF167,160$3.42$229.69K285,432Direct
Filing footnotes · 1
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Brady Patrick PriestCEO of Clover Care Services
4
Filed May 13, 2026Period of report May 13, 20260001938197-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 13, 2026
Class A Common Stock98,039$3.52$345.10K2,040,222Direct
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Mar 18, 2026Period of report Mar 18, 20260001839066-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 18, 2026
Class A Common StockF15,833$1.91$11.14K2,716,735Direct
Filing footnotes · 1
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.96, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:
Open on SEC EDGAR
Brady Patrick PriestCEO of Home Care
4
Filed Mar 5, 2026Period of report Mar 4, 20260001938197-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 4, 2026
Class A Common StockF1175,000$2.17$379.75K1,998,584Direct
Filing footnotes · 1
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.16 to $2.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jan 20, 2026Period of report Jan 15, 20260001801170-26-000024
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 20, 2026
Class A Common StockF24,597$2.58$11.86K2,737,700Direct
Filing footnotes · 2
  1. F1Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on January 15, 2026, due to the vesting of 6.25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date.
  2. F2The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.47 to $2.63, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Jan 7, 2026Period of report Jan 7, 20260001839066-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 7, 2026
Class A Common StockF12,102$2.53$5.32K2,757,029Direct
Filing footnotes · 1
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.61, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Open on SEC EDGAR
Jamie L. ReynosoCEO, Medicare Advantage
4Rule 10b5-1 plan disclosed
Filed Dec 18, 2025Period of report Dec 18, 20250001839066-25-000029
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 18, 2025
Class A Common StockF14,913$2.61$12.82K2,767,240Direct
Filing footnotes · 1
  1. F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.58 to $2.64, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.